Catalyst Pharmaceutical CPRX Equity Securities (FV-NI) - Non-Current

Other financials

Revenue$149.4M+5.6%

Gross profit$134.9M+9.2%

Operating income$73.2M+15.6%

Net income$63.7M+12.3%

EPS (diluted)$0.50+11.1%

Cash & equivalents$755.9M+30.2%

Total debt$2.7M-13.3%

Total equity$1.0B+27.5%

Total assets$1.1B+26.3%

Operating cash flow$59.6M-0.8%

CapEx$27.0K—

Free cash flow$59.6M-0.8%

Market cap$3.84B+2.7%

Enterprise value$3.09B-4.1%

P/E17.4×-1.6×

P/S6.4×-0.6×

Gross margin86%-0.2pp

Operating margin44.8%+1.6pp

Net margin37.1%+0.2pp

FCF margin34.9%-15.2pp

Return on equity24.5%-4.6pp

Debt / equity0×0.0×

Current ratio7.1×+1.0×

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFVNINoncurrent.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Catalyst Pharmaceutical's equity securities (FV-NI) - non-current?: Catalyst Pharmaceutical (CPRX) reported equity securities (FV-NI) - non-current of $27.29M in Q1 2026.
How has Catalyst Pharmaceutical's equity securities (FV-NI) - non-current changed year-over-year?: Catalyst Pharmaceutical's equity securities (FV-NI) - non-current increased by 12.7% year-over-year, from $24.21M to $27.29M.